eMedicine Specialties > Ophthalmology > Retina

Retinitis, CMV

Author: Michael Altaweel, MD, FRCS(C), Associate Professor, Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health
Coauthor(s): Matthew D Reed, MD, Fellow, Department of Ophthalmology and Visual Sciences, University of Wisconsin Clinical Science Center
Contributor Information and Disclosures

Updated: Apr 18, 2006

Introduction

Background

Cytomegalovirus (CMV) is a ubiquitous DNA virus that infects the majority of the adult population. In the immunocompetent host, infection is generally asymptomatic or limited to a mononucleosislike syndrome. Like many other herpesviruses, CMV remains latent in the host and may reactivate if host immunity is compromised.

In immunocompromised individuals, primary infection or reactivation of latent virus can lead to opportunistic infection of multiple organ systems. In the eye, CMV most commonly presents as a viral necrotizing retinitis with a characteristic ophthalmoscopic appearance. Untreated CMV retinitis inexorably progresses to visual loss and blindness.

Multiple antiviral agents, delivered locally, systemically, or in combination, are currently in use to delay or arrest the progress of the disease. In addition, highly active antiretroviral therapy (HAART) for HIV infection has revolutionized the treatment of CMV retinitis by allowing immune reconstitution in many individuals.

Pathophysiology

Clinical CMV infection can affect multiple organ systems, including the skin (eg, rashes, ulcers, pustules), lungs (eg, interstitial pneumonitis), gastrointestinal tract (eg, colitis, esophagitis), peripheral nerves (eg, radiculopathy and myelopathy), the brain (eg, meningoencephalitis), and the eye (eg, retinitis, optic neuritis).

Frequency

United States

CMV is ubiquitous, infecting 50-80% of the adult population. Clinically evident disease is found almost exclusively in immunosuppressed individuals. Prior to HAART, CMV occurred in 25-40% of all AIDS patients and was the most common opportunistic infection in AIDS patients with a CD4 count below 50 cells/mL. While HAART has decreased the incidence of CMV retinitis by 55-83%, the decline in AIDS-related mortality has led to an increase in the number of patients with CMV disease.

CMV retinitis remains a leading cause of visual loss in patients with AIDS and is increasing in organ transplant recipients as the number of those procedures performed each year increases.

International

The frequency of disease in other developed countries is equivalent. The incidence of CMV in developing countries mirrors the spread of the HIV virus and the availability of antiretroviral medications.

Mortality/Morbidity

CMV retinitis frequently results in considerable loss of visual acuity, and, without treatment, it almost universally leads to blindness. Severe visual loss primarily occurs from the direct spread of retinitis into the posterior pole, affecting central vision, or from retinal detachment (RD) secondary to multiple retinal breaks in the peripheral, necrotic retina.

Early and aggressive treatment with antiviral medication for both CMV and HIV, combined with improved surgical techniques for RD repair, has helped to improve the visual outcomes in these patients.

  • Untreated CMV leads to progressive visual loss and eventual blindness.
  • Retinal detachment occurs in up to 29%.
  • Retinitis permanently destroys the retina; lesions change appearance with treatment but do not become smaller.
  • If the CD4 count is less than 100 cells/mL, CMV retinitis will develop in 20-30% of patients over a year, although retinitis typically develops if the CD4 count is reduced below 50 cells/mL. Of these patients, 5-10% develop other systemic infections (eg, pneumonitis, colitis, esophagitis).
  • With the advent of HAART and immune reconstitution, some patients suffer from a relatively new condition known as immune recovery uveitis (IRU). IRU occurs when the poor immune response of an immunocompromised individual is suddenly increased as the patients restored immune system recognizes and reacts to viral antigens in the retina. This reaction can lead to several complications, including uveitis, leading to hypotony, cataract, and glaucoma; epiretinal membrane (ERM); and cystoid macular edema (CME).

Sex

Although the incidence of CMV retinitis is the same among men and women, the prevalence is higher in men than in women because of the higher prevalence of AIDS in men. The prevalence of CMV retinitis in the heterosexual community has been steadily increasing.

Age

The age of most individuals developing CMV retinitis is 20-50 years.

Clinical

History

Presenting symptoms vary depending on the location of retinal involvement. Posterior lesions present with diminished visual acuity. More peripheral lesions initially can be asymptomatic. Floaters often are noted if significant vitritis is present. The eye usually is white and quiet.

  • Active CMV retinitis usually is found in conjunction with immunosuppression, whether from AIDS, leukemia, or use of chemotherapy. These points are important in evaluating the patient history. Rarely, CMV retinitis is the first presenting manifestation of AIDS.
  • Natural history
    • CMV retinitis is a slowly progressive disease, requiring weeks to months to involve the entire retina. Vision is lost with involvement of the posterior pole (macula or optic nerve) or retinal detachment.
    • Initial reports described CMV retinitis as an end-stage disease, which indicated a life expectancy of 6 weeks. With the use of antiviral medications, the average survival after diagnosis ranged from 5.5-8 months. The advent of HAART has prolonged survival to years in some instances, and it has allowed discontinuation of medications targeted against CMV retinitis if clinical resolution occurs and the immune status recovers (reflected by a CD4 count of >100 cells/mL).
  • After initiation of therapy, some advance of the leading edge of retinitis may be noted. This usually is not a treatment failure but rather the revealing of an area of subclinical infection that was not previously evident.

Physical

Patients with suspected CMV retinitis should have a complete ocular examination of both eyes. A careful examination should include the following:

  • Carefully check and record the patient's best corrected visual acuity as a baseline. Check for visual field defects that could represent optic nerve damage, RD, or CNS disease from AIDS-related brain diseases (eg, encephalitis, stroke, CNS lymphoma). Ocular motility should be assessed as part of a cranial nerve examination. Pupils should be checked for a relative afferent pupillary defect indicating optic nerve involvement.
  • External examination of the lids and adnexa should be performed for other AIDS associated findings, such as Kaposi sarcoma or lymphoma.
  • A thorough slit lamp examination should show a white and quiet conjunctiva. A red hot eye in an immunocompromised patient should alert the clinician to another possible diagnosis. Fine, stellate keratitic precipitates (KP) characteristic of CMV may be seen on the corneal endothelium. Uveitis may be present in the anterior chamber and, if severe, may require treatment. The level of vitritis can be assessed in the anterior vitreous and may be important for monitoring response to treatment or the occurrence of IRU.
  • A dilated fundus examination with indirect ophthalmoscopy is essential for assessing the location and extent of retinal involvement as well as for evaluating for retinal breaks or detachment. Retinal lesions have several characteristics, as follows:
    • Lesions that present posteriorly appear along retinal vessels as large areas of thick white infiltrate accompanied by retinal hemorrhage described as "pizza pie" or "cheese pizza" in appearance.
    • The peripheral type of lesion demonstrates a more granular appearance with satellite lesions and less hemorrhage. Behind the advancing border is necrotic retina with mottled pigmentation from hyperplasia of the retinal pigment epithelium (RPE).
    • Lesions usually begin peripherally and spread posteriorly in a contiguous fashion. However, multiple unconnected lesions are frequent, and involvement of the posterior pole with minimal peripheral disease is possible.
    • Retinitis follows the nerve fiber layer.
    • Retinitis produces wide areas of necrosis, scarring, and atrophy.
    • Even severe retinitis is usually accompanied by minimal vitritis in the immunocompromised patient. If HAART is instituted and immune reconstitution occurs, then IRU with severe anterior and posterior uveitis may occur.
    • Extensive vascular sheathing, often described as frosted branch angiitis, is a known but uncommon appearance.
    • Retinal vascular occlusion/nonperfusion can be seen on fluorescein angiogram.
  • Peripheral holes and tears frequently occur in areas of necrosis.
  • Rate of progression of untreated retinitis is 250-350 µm per week. Skip lesions can occur.
  • Serial examinations may be necessary at early stages to distinguish CMV retinitis from HIV retinopathy with multiple cotton-wool spots.
  • Optic neuritis can develop without apparent retinitis.
  • Most patients with CMV retinitis will initially present with unilateral disease. Untreated, the immunocompromised patient has a 50% risk of developing disease in the contralateral eye within 6 months. This is reduced to 20% with antiviral treatment and further reduced with HAART.

Causes

Any immunosuppression due to disease or medication may allow clinical CMV infection to develop.

  • Acquired immune deficiency syndrome
  • Leukemia, lymphoma, and aplastic anemia
  • Use of immunosuppressive chemotherapy
  • Organ transplant recipients

More on Retinitis, CMV

Overview: Retinitis, CMV
Differential Diagnoses & Workup: Retinitis, CMV
Treatment & Medication: Retinitis, CMV
Follow-up: Retinitis, CMV
Multimedia: Retinitis, CMV
References
[ CLOSE WINDOW ]

References

  1. Akerele T, Lightman S. Current and novel agents for the treatment of cytomegalovirus retinitis. Drugs R D. Nov 1999;2(5):289-97. [Medline].

  2. Althaus C, Loeffler KU, Schimkat M, et al. Prophylactic argon laser coagulation for rhegmatogenous retinal detachment in AIDS patients with cytomegalovirus retinitis. Graefes Arch Clin Exp Ophthalmol. May 1998;236(5):359-64. [Medline].

  3. Ambati J, Wynne KB, Angerame MC, Robinson MR. Anterior uveitis associated with intravenous cidofovir use in patients with cytomegalovirus retinitis. Br J Ophthalmol. Oct 1999;83(10):1153-8. [Medline].

  4. Azen SP, Scott IU, Flynn HW Jr, et al. Silicone oil in the repair of complex retinal detachments. A prospective observational multicenter study. Ophthalmology. Sep 1998;105(9):1587-97. [Medline].

  5. Bachman DM, Bruni LM, DiGioia RA, et al. Visual field testing in the management of cytomegalovirus retinitis. Ophthalmology. Sep 1992;99(9):1393-9. [Medline].

  6. Baldassano V, Dunn JP, Feinberg J, Jabs DA. Cytomegalovirus retinitis and low CD4+ T-lymphocyte counts. N Engl J Med. Sep 7 1995;333(10):670. [Medline].

  7. Baumal CR, Levin AV, Read SE. Cytomegalovirus retinitis in immunosuppressed children. Am J Ophthalmol. May 1999;127(5):550-8. [Medline].

  8. Baumal CR, Reichel E. Management of cytomegalovirus-related rhegmatogenous retinal detachments. Ophthalmic Surg Lasers. Nov 1998;29(11):916-25. [Medline].

  9. Biswas J, Raizada S, Gopal L, et al. Bilateral frosted branch angiitis and cytomegalovirus retinitis in acquired immunodeficiency syndrome. Indian J Ophthalmol. Sep 1999;47(3):195-7. [Medline].

  10. Biswas J, Madhavan HN, George AE, et al. Ocular lesions associated with HIV infection in India: a series of 100 consecutive patients evaluated at a referral center. Am J Ophthalmol. Jan 2000;129(1):9-15. [Medline].

  11. Bloom PA, Sandy CJ, Migdal CS, et al. Visual prognosis of AIDS patients with cytomegalovirus retinitis. Eye. 1995;9 ( Pt 6):697-702. [Medline].

  12. Bowen EF, Griffiths PD, Davey CC, et al. Lessons from the natural history of cytomegalovirus. AIDS. Nov 1996;10 Suppl 1:S37-41. [Medline].

  13. Bowen EF, Wilson P, Atkins M, et al. Natural history of untreated cytomegalovirus retinitis. Lancet. Dec 23-30 1995;346(8991-8992):1671-3. [Medline].

  14. Boyer DS, Posalski J. Potential complication associated with removal of ganciclovir implants. Am J Ophthalmol. Mar 1999;127(3):349-50. [Medline].

  15. Boyraz-Ikiz HD, Witmer JP, Frissen PH. Cytomegalovirus (re)activation plays no role in the ocular vitritis observed after initiation of highly active antiretroviral therapy. AIDS. May 7 1999;13(7):867. [Medline].

  16. Brody JM, Butrus SI, Laby DM, et al. Anterior segment findings in AIDS patients with cytomegalovirus retinitis. Graefes Arch Clin Exp Ophthalmol. Jun 1995;233(6):374-6. [Medline].

  17. Brown F, Banken L, Saywell K, Arum I. Pharmacokinetics of valganciclovir and ganciclovir following multiple oral dosages of valganciclovir in HIV- and CMV-seropositive volunteers. Clin Pharmacokinet. Aug 1999;37(2):167-76. [Medline].

  18. Chernoff DN, Miner RC, Hoo BS, et al. Quantification of cytomegalovirus DNA in peripheral blood leukocytes by a branched-DNA signal amplification assay. J Clin Microbiol. Nov 1997;35(11):2740-4. [Medline].

  19. Cochereau I, Doan S, Diraison MC, et al. Uveitis in patients treated with intravenous cidofovir. Ocul Immunol Inflamm. Dec 1999;7(3-4):223-9. [Medline].

  20. Cvetkovic RS, Wellington K. Valganciclovir: a review of its use in the management of CMV infection and disease in immunocompromised patients. Drugs. 2005;65(6):859-78. [Medline].

  21. D''Aquila R, Walker B. Exploring the benefits and limits of highly active antiretroviral therapy. JAMA. Nov 3 1999;282(17):1668-9. [Medline].

  22. Danner SA, Matheron S. Cytomegalovirus retinitis in AIDS patients: a comparative study of intravenous and oral ganciclovir as maintenance therapy. AIDS. Dec 1996;10 Suppl 4:S7-11. [Medline].

  23. Davis JL. Differential diagnosis of CMV retinitis. Ocul Immunol Inflamm. Dec 1999;7(3-4):159-66. [Medline].

  24. Davis JL, Hummer J, Feuer WJ. Laser photocoagulation for retinal detachments and retinal tears in cytomegalovirus retinitis. Ophthalmology. Dec 1997;104(12):2053-60; discussion 2060-1. [Medline].

  25. Davis JL, Serfass MS, Lai MY, et al. Silicone oil in repair of retinal detachments caused by necrotizing retinitis in HIV infection. Arch Ophthalmol. Nov 1995;113(11):1401-9. [Medline].

  26. Derzko-Dzulynsky LA, Berger AR, Berinstein NL, Berinstein NL. Cytomegalovirus retinitis and low-grade non-Hodgkin''s lymphoma: case report and review of the literature. Am J Hematol. Mar 1998;57(3):228-32. [Medline].

  27. Desatnik HR, Foster RE, Lowder CY. Treatment of clinically resistant cytomegalovirus retinitis with combined intravitreal injections of ganciclovir and foscarnet. Am J Ophthalmol. Jul 1996;122(1):121-3. [Medline].

  28. Doan S, Cochereau I, Guvenisik N, et al. Cytomegalovirus retinitis in HIV-infected patients with and without highly active antiretroviral therapy. Am J Ophthalmol. Aug 1999;128(2):250-1. [Medline].

  29. Drew WL, Ives D, Lalezari JP, et al. Oral ganciclovir as maintenance treatment for cytomegalovirus retinitis in patients with AIDS. Syntex Cooperative Oral Ganciclovir Study Group. N Engl J Med. Sep 7 1995;333(10):615-20. [Medline].

  30. Drusano GL, Aweeka F, Gambertoglio J, et al. Relationship between foscarnet exposure, baseline cytomegalovirus (CMV) blood culture and the time to progression of CMV retinitis in HIV- positive patients. AIDS. Sep 1996;10(10):1113-9. [Medline].

  31. Egbert PR, Pollard RB, Gallagher JG, Merigan TC. Cytomegalovirus retinitis in immunosuppressed hosts. II. Ocular manifestations. Ann Intern Med. Nov 1980;93(5):664-70. [Medline].

  32. Elkins BS, Holland GN, Opremcak EM, et al. Ocular toxoplasmosis misdiagnosed as cytomegalovirus retinopathy in immunocompromised patients. Ophthalmology. Mar 1994;101(3):499-507. [Medline].

  33. Erice A, Jordan MC, Chace BA, et al. Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. JAMA. Jun 12 1987;257(22):3082-7. [Medline].

  34. Freeman WR, Friedberg DN, Berry C, et al. Risk factors for development of rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis. Am J Ophthalmol. Dec 15 1993;116(6):713-20. [Medline].

  35. Freeman WR. Retinal detachment in cytomegalovirus retinitis: should our approach be changed?. Retina. 1999;19(4):271-3. [Medline].

  36. Fuchs AV, Wolf E, Scheider A, Jager H, Kampik A. [Cytomegalovirus (CMV) retinitis in AIDS. Gancilovir implantation in comparison with systemic therapy]. Ophthalmologe. Jan 1999;96(1):11-5. [Medline].

  37. Gilbert C, Handfield J, Toma E, et al. Emergence and prevalence of cytomegalovirus UL97 mutations associated with ganciclovir resistance in AIDS patients. AIDS. Jan 22 1998;12(2):125-9. [Medline].

  38. Goldberg DE, Wang H, Azen SP. Long term visual outcome of patients with cytomegalovirus retinitis treated with highly active antiretroviral therapy. Br J Ophthalmol. Jul 2003;87(7):853-5. [Medline].

  39. Grant AD, Djomand G, De Cock KM. Natural history and spectrum of disease in adults with HIV/AIDS in Africa. AIDS. 1997;11 Suppl B:S43-54. [Medline].

  40. Gross JG, Bozzette SA, Mathews WC, et al. Longitudinal study of cytomegalovirus retinitis in acquired immune deficiency syndrome. Ophthalmology. May 1990;97(5):681-6. [Medline].

  41. Guembel HO, Krieglsteiner S, Rosenkranz C, et al. Complications after implantation of intraocular devices in patients with cytomegalovirus retinitis. Graefes Arch Clin Exp Ophthalmol. Oct 1999;237(10):824-9. [Medline].

  42. Harb GE, Bacchetti P, Jacobson MA. Survival of patients with AIDS and cytomegalovirus disease treated with ganciclovir or foscarnet. AIDS. Aug 1991;5(8):959-65. [Medline].

  43. Hardy WD. Combined ganciclovir and recombinant human granulocyte-macrophage colony-stimulating factor in the treatment of cytomegalovirus retinitis in AIDS patients. J Acquir Immune Defic Syndr. 1991;4 Suppl 1:S22-8. [Medline].

  44. Hardy WD. Management strategies for patients with cytomegalovirus retinitis. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14 Suppl 1:S7-12. [Medline].

  45. Holbrook JT, Davis MD, Hubbard LD, et al. Risk factors for advancement of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. Studies of Ocular Complications of AIDS Research Group. Arch Ophthalmol. Sep 2000;118(9):1196-204. [Medline].

  46. Holbrook JT, Jabs DA, Weinberg DV. Visual loss in patients with cytomegalovirus retinitis and acquired immunodeficiency syndrome before widespread availability of highly active antiretroviral therapy. Arch Ophthalmol. Jan 2003;121(1):99-107. [Medline].

  47. Holland GN, Buhles WC Jr, Mastre B, Kaplan HJ. A controlled retrospective study of ganciclovir treatment for cytomegalovirus retinopathy. Use of a standardized system for the assessment of disease outcome. UCLA CMV Retinopathy. Study Group. Arch Ophthalmol. Dec 1989;107(12):1759-66. [Medline].

  48. Holland GN. New issues in the management of patients with AIDS-related cytomegalovirus retinitis. Arch Ophthalmol. May 2000;118(5):704-6. [Medline].

  49. Holland GN. Treatment options for cytomegalovirus retinitis: a time for reassessment. Arch Ophthalmol. Nov 1999;117(11):1549-50. [Medline].

  50. Hoshino Y, Nagata Y, Taguchi H, et al. Role of the cytomegalovirus (CMV)-antigenemia assay as a predictive and follow-up detection tool for CMV disease in AIDS patients. Microbiol Immunol. 1999;43(10):959-65. [Medline].

  51. Jabs DA, Enger C, Dunn JP, et al. Cytomegalovirus retinitis and viral resistance: 3. Culture results. CMV Retinitis and Viral Resistance Study Group. Am J Ophthalmol. Oct 1998;126(4):543-9. [Medline].

  52. Jabs DA, Enger C, Forman M, et al. Incidence of foscarnet resistance and cidofovir resistance in patients treated for cytomegalovirus retinitis. The Cytomegalovirus Retinitis and Viral Resistance Study Group. Antimicrob Agents Chemother. Sep 1998;42(9):2240-4. [Medline].

  53. Jabs DA. Design of clinical trials for drug combinations: cytomegalovirus retinitis--foscarnet and ganciclovir. The CMV retinitis retreatment trial. Antiviral Res. Jan 1996;29(1):69-71. [Medline].

  54. Jabs DA. Controversies in the treatment of cytomegalovirus retinitis: foscarnet versus ganciclovir. Infect Agents Dis. Sep 1995;4(3):131-42. [Medline].

  55. Jabs DA, Van Natta ML, Thorne JE, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 2. Second eye involvement and retinal detachment. Ophthalmology. Dec 2004;111(12):2232-9. [Medline].

  56. Jabs DA, Van Natta ML, Thorne JE, et al. Course of cytomegalovirus retinitis in the era of highly active antiretroviral therapy: 1. Retinitis progression. Ophthalmology. Dec 2004;111(12):2224-31. [Medline].

  57. Jacobson MA, Wilson S, Stanley H, et al. Phase I study of combination therapy with intravenous cidofovir and oral ganciclovir for cytomegalovirus retinitis in patients with AIDS. Clin Infect Dis. Mar 1999;28(3):528-33. [Medline].

  58. Jensen OA, Gerstoft J, Thomsen HK, Marner K. Cytomegalovirus retinitis in the acquired immunodeficiency syndrome (AIDS). Light-microscopical, ultrastructural and immunohistochemical examination of a case. Acta Ophthalmol (Copenh). Feb 1984;62(1):1-9. [Medline].

  59. Karavellas MP, Plummer DJ, Macdonald JC, et al. Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. J Infect Dis. Mar 1999;179(3):697-700. [Medline].

  60. Kaulfersch W, Urban C, Hauer C, et al. Successful treatment of CMV retinitis with ganciclovir after allogeneic marrow transplantation. Bone Marrow Transplant. Sep 1989;4(5):587-9. [Medline].

  61. Kempen JH, Jabs DA, Wilson LA. Risk of vision loss in patients with cytomegalovirus retinitis and the acquired immunodeficiency syndrome. Arch Ophthalmol. Apr 2003;121(4):466-76. [Medline].

  62. Kempen JH, Jabs DA, Wilson LA. Incidence of cytomegalovirus (CMV) retinitis in second eyes of patients with the acquired immune deficiency syndrome and unilateral CMV retinitis. Am J Ophthalmol. Jun 2005;139(6):1028-34. [Medline].

  63. Kestelyn P. The epidemiology of CMV retinitis in Africa. Ocul Immunol Inflamm. Dec 1999;7(3-4):173-7. [Medline].

  64. Knox CM, Chandler D, Short GA, Margolis TP. Polymerase chain reaction-based assays of vitreous samples for the diagnosis of viral retinitis. Use in diagnostic dilemmas. Ophthalmology. Jan 1998;105(1):37-44; discussion 44-5. [Medline].

  65. Kuppermann BD, Quiceno JI, Flores-Aguilar M, et al. Intravitreal ganciclovir concentration after intravenous administration in AIDS patients with cytomegalovirus retinitis: implications for therapy. J Infect Dis. Dec 1993;168(6):1506-9. [Medline].

  66. Lalezari JP, Holland GN, Kramer F, et al. Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol. Apr 1 1998;17(4):339-44. [Medline].

  67. Lalezari JP. Cidofovir: a new therapy for cytomegalovirus retinitis. J Acquir Immune Defic Syndr Hum Retrovirol. 1997;14 Suppl 1:S22-6. [Medline].

  68. Lam TT, Fu J, Chu R, et al. Intravitreal delivery of ganciclovir in rabbits by transscleral iontophoresis. J Ocul Pharmacol. Fall 1994;10(3):571-5. [Medline].

  69. Lietman PS. Clinical pharmacology: foscarnet. Am J Med. Feb 14 1992;92(2A):8S-11S. [Medline].

  70. Lim JI, Wolitz RA, Dowling AH, et al. Visual and anatomic outcomes associated with posterior segment complications after ganciclovir implant procedures in patients with AIDS and cytomegalovirus retinitis. Am J Ophthalmol. Mar 1999;127(3):288-93. [Medline].

  71. Lim JI, Enger C, Haller JA, et al. Improved visual results after surgical repair of cytomegalovirus- related retinal detachments. Ophthalmology. Feb 1994;101(2):264-9. [Medline].

  72. Liu JH, Hsu WM, Wong WW, et al. Using conjunctival swab with polymerase chain reaction to aid diagnosis of cytomegalovirus retinitis in AIDS patients. Ophthalmologica. 2000;214(2):126-30. [Medline].

  73. Macdonald JC, Torriani FJ, Morse LS, et al. Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping CMV maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis. May 1998;177(5):1182-7. [Medline].

  74. Mansor AM, Li HK. Cytomegalovirus optic neuritis: characteristics, therapy and survival. Ophthalmologica. 1995;209(5):260-6. [Medline].

  75. Mansour AM, Li HK. Frosted retinal periphlebitis in the acquired immunodeficiency syndrome. Ophthalmologica. 1993;207(4):182-6. [Medline].

  76. Margolis TP. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. Surv Ophthalmol. Mar-Apr 2000;44(5):455. [Medline].

  77. Martin DF, Kuppermann BD, Wolitz RA, et al. Oral ganciclovir for patients with cytomegalovirus retinitis treated with a ganciclovir implant. Roche Ganciclovir Study Group. N Engl J Med. Apr 8 1999;340(14):1063-70. [Medline].

  78. Martin DF, Dunn JP, Davis JL, et al. Use of the ganciclovir implant for the treatment of cytomegalovirus retinitis in the era of potent antiretroviral therapy: recommendations of the International AIDS Society-USA panel. Am J Ophthalmol. Mar 1999;127(3):329-39. [Medline].

  79. Martin DF, Ferris FL, Parks DJ, et al. Ganciclovir implant exchange. Timing, surgical procedure, and complications. Arch Ophthalmol. Nov 1997;115(11):1389-94. [Medline].

  80. Martin DF, Sierra-Madero J, Walmsley S. A controlled trial of valganciclovir as induction therapy for cytomegalovirus retinitis. N Engl J Med. Apr 11 2002;346(15):1119-26. [Medline].

  81. Marwick C. First "antisense" drug will treat CMV retinitis. JAMA. Sep 9 1998;280(10):871. [Medline].

  82. McAuliffe PF, Hall MJ, Castro-Malaspina H, Heinemann MH. Use of the ganciclovir implant for treating cytomegalovirus retinitis secondary to immunosuppression after bone marrow transplantation. Am J Ophthalmol. May 1997;123(5):702-3. [Medline].

  83. McCutchan JA. Clinical impact of cytomegalovirus infections of the nervous system in patients with AIDS. Clin Infect Dis. Oct 1995;21 Suppl 2:S196-201. [Medline].

  84. McCutchan JA. Cytomegalovirus infections of the nervous system in patients with AIDS. Clin Infect Dis. Apr 1995;20(4):747-54. [Medline].

  85. Meffert SA, Ai E. Laser photocoagulation prophylaxis for CMV retinal detachments. Ophthalmology. Aug 1998;105(8):1353-5. [Medline].

  86. Mitchell SM, Membrey WL, Youle MS, et al. Cytomegalovirus retinitis after the initiation of highly active antiretroviral therapy: a 2 year prospective study. Br J Ophthalmol. Jun 1999;83(6):652-5. [Medline].

  87. Murray HW, Knox DL, Green WR, Susel RM. Cytomegalovirus retinitis in adults. A manifestation of disseminated viral infection. Am J Med. Oct 1977;63(4):574-84. [Medline].

  88. Musch DC, Martin DF, Gordon JF, et al. Treatment of cytomegalovirus retinitis with a sustained-release ganciclovir implant. The Ganciclovir Implant Study Group. N Engl J Med. Jul 10 1997;337(2):83-90. [Medline].

  89. Nasemann JE, Mutsch A, Wiltfang R, Klauss V. Early pars plana vitrectomy without buckling procedure in cytomegalovirus retinitis-induced retinal detachment. Retina. 1995;15(2):111-6. [Medline].

  90. Nasir MA, Jaffe GJ. Cytomegalovirus retinitis associated with Hodgkin''s disease. Retina. 1996;16(4):324-7. [Medline].

  91. Nguyen QD, Kempen JH, Bolton SG, et al. Immune recovery uveitis in patients with AIDS and cytomegalovirus retinitis after highly active antiretroviral therapy. Am J Ophthalmol. May 2000;129(5):634-9. [Medline].

  92. Nichols WG, Boeckh M. Recent advances in the therapy and prevention of CMV infections. J Clin Virol. Feb 2000;16(1):25-40. [Medline].

  93. Pecorella I, Ciardi A, Credendino A, et al. Ocular, cerebral and systemic interrelationships of cytomegalovirus infection in a post-mortem study of AIDS patients. Eye. Dec 1999;13 ( Pt 6):781-5. [Medline].

  94. Pertel P, Hirschtick R, Phair J, et al. Risk of developing cytomegalovirus retinitis in persons infected with the human immunodeficiency virus. J Acquir Immune Defic Syndr. 1992;5(11):1069-74. [Medline].

  95. Phillips AN, Lazzarin A, Gonzales-Lahoz J, et al. Factors associated with the CD4+ lymphocyte count at diagnosis of acquired immunodeficiency syndrome. The AIDS IN EUROPE Study Group. J Clin Epidemiol. Nov 1996;49(11):1253-8. [Medline].

  96. Plosker GL, Noble S. Cidofovir: a review of its use in cytomegalovirus retinitis in patients with AIDS. Drugs. Aug 1999;58(2):325-45. [Medline].

  97. Pollard RB. CMV retinitis: ganciclovir/monoclonal antibody. Antiviral Res. Jan 1996;29(1):73-5. [Medline].

  98. Rahhal FM, Arevalo JF, Munguia D, et al. Intravitreal cidofovir for the maintenance treatment of cytomegalovirus retinitis. Ophthalmology. Jul 1996;103(7):1078-83. [Medline].

  99. Rasmussen L, Morris S, Zipeto D, et al. Quantitation of human cytomegalovirus DNA from peripheral blood cells of human immunodeficiency virus-infected patients could predict cytomegalovirus retinitis. J Infect Dis. Jan 1995;171(1):177-82. [Medline].

  100. Ross WH, Bryan JS, Barloon AS. Management of retinal detachments secondary to cytomegalovirus retinitis. Can J Ophthalmol. Jun 1994;29(3):129-33. [Medline].

  101. Roth DB, Feuer WJ, Blenke AJ, Davis JL. Treatment of recurrent cytomegalovirus retinitis with the ganciclovir implant. Am J Ophthalmol. Mar 1999;127(3):276-82. [Medline].

  102. Ruhswurm I, Ries E, Krepler K, et al. Control of cytomegalovirus retinitis after combination antiretroviral therapy. Acta Ophthalmol Scand. Aug 1999;77(4):471-3. [Medline].

  103. Sanborn GE, Anand R, Torti RE, et al. Sustained-release ganciclovir therapy for treatment of cytomegalovirus retinitis. Use of an intravitreal device. Arch Ophthalmol. Feb 1992;110(2):188-95. [Medline].

  104. Sandy CJ, Ferris JD, Bloom PA, et al. Screening for cytomegalovirus retinitis in HIV-positive and AIDS patients. QJM. Dec 1995;88(12):899-903. [Medline].

  105. Sandy CJ, Bloom PA, Graham EM, et al. Retinal detachment in AIDS-related cytomegalovirus retinitis. Eye. 1995;9 ( Pt 3):277-81. [Medline].

  106. Saran BR, Pomilla PV. Retinal vascular nonperfusion and retinal neovascularization as a consequence of cytomegalovirus retinitis and cryptococcal choroiditis. Retina. 1996;16(6):510-2. [Medline].

  107. Schaller UC, MacDonald JC, Mueller AJ, et al. Removal of silicone oil with vision improvement after rhegmatogenous retinal detachment following CMV retinitis in patients with AIDS. Retina. 1999;19(6):495-8. [Medline].

  108. Smith CL. Local therapy for cytomegalovirus retinitis. Ann Pharmacother. Feb 1998;32(2):248-55. [Medline].

  109. Song MK, Karavellas MP, MacDonald JC, et al. Characterization of reactivation of cytomegalovirus retinitis in patients healed after treatment with highly active antiretroviral therapy. Retina. 2000;20(2):151-5. [Medline].

  110. Soriano V, Dona C, Rodriguez-Rosado R, et al. Discontinuation of secondary prophylaxis for opportunistic infections in HIV-infected patients receiving highly active antiretroviral therapy. AIDS. Mar 10 2000;14(4):383-6. [Medline].

  111. Spector SA. Oral ganciclovir. Adv Exp Med Biol. 1999;458:121-7. [Medline].

  112. Spector SA, McKinley GF, Lalezari JP, et al. Oral ganciclovir for the prevention of cytomegalovirus disease in persons with AIDS. Roche Cooperative Oral Ganciclovir Study Group. N Engl J Med. Jun 6 1996;334(23):1491-7. [Medline].

  113. Spector SA, Busch DF, Follansbee S, et al. Pharmacokinetic, safety, and antiviral profiles of oral ganciclovir in persons infected with human immunodeficiency virus: a phase I/II study. AIDS Clinical Trials Group, and Cytomegalovirus Cooperative Study Group. J Infect Dis. Jun 1995;171(6):1431-7. [Medline].

  114. Spector SA, Weingeist T, Pollard RB, et al. A randomized, controlled study of intravenous ganciclovir therapy for cytomegalovirus peripheral retinitis in patients with AIDS. AIDS Clinical Trials Group and Cytomegalovirus Cooperative Study Group. J Infect Dis. Sep 1993;168(3):557-63. [Medline].

  115. Squires KE. Oral ganciclovir for cytomegalovirus retinitis in patients with AIDS: results of two randomized studies. AIDS. Dec 1996;10 Suppl 4:S13-8. [Medline].

  116. Stalder N, Sudre P, Olmari M, et al. Cytomegalovirus retinitis: decreased risk of bilaterality with increased use of systemic treatment. Swiss HIV Cohort Study Group. Clin Infect Dis. Apr 1997;24(4):620-4. [Medline].

  117. Stier PA, Glazer LC, Garretson BR, Deutsch TA. Surgical repair of retinal detachment secondary to cytomegalovirus retinitis. Ophthalmic Surg Lasers. Apr 1999;30(4):289-94. [Medline].

  118. Studies of Ocular Complications of AIDS (SOCA) Research Group. Long-term follow-up of patients with AIDS treated with parenteral cidofovir for cytomegalovirus retinitis: the HPMPC Peripheral Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS. AIDS. Jul 28 2000;14(11):1571-81. [Medline].

  119. Studies of Ocular Complications of AIDS (SOCA) Research Group. MSL-109 adjuvant therapy for cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome: the Monoclonal Antibody Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS Research Group. AIDS Clinical Trials Group. Arch Ophthalmol. Dec 1997;115(12):1528-36. [Medline].

  120. Studies of Ocular Complications of AIDS (SOCA) Research Group. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 5. Clinical features of cytomegalovirus retinitis at diagnosis. Studies of ocular complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Am J Ophthalmol. Aug 1997;124(2):141-57. [Medline].

  121. Studies of Ocular Complications of AIDS (SOCA) Research Group. Rhegmatogenous retinal detachment in patients with cytomegalovirus retinitis: the Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. The Studies of Ocular Complications of AIDS (SOCA) Research Group in Collaboration with the AIDS Clinical Trials G. Am J Ophthalmol. Jul 1997;124(1):61-70. [Medline].

  122. Studies of Ocular Complications of AIDS (SOCA) Research Group. Cytomegalovirus (CMV) culture results, drug resistance, and clinical outcome in patients with AIDS and CMV retinitis treated with foscarnet or ganciclovir. Studies of Ocular Complications of AIDS (SOCA) in collaboration with the AIDS Clinical Trial Gr. J Infect Dis. Jul 1997;176(1):50-8. [Medline].

  123. Studies of Ocular Complications of AIDS (SOCA) Research Group. Parenteral cidofovir for cytomegalovirus retinitis in patients with AIDS: the HPMPC peripheral cytomegalovirus retinitis trial. A randomized, controlled trial. Studies of Ocular complications of AIDS Research Group in Collaboration with the AIDS Clini. Ann Intern Med. Feb 15 1997;126(4):264-74. [Medline].

  124. Studies of Ocular Complications of AIDS (SOCA) Research Group. Combination foscarnet and ganciclovir therapy vs monotherapy for the treatment of relapsed cytomegalovirus retinitis in patients with AIDS. The Cytomegalovirus Retreatment Trial. The Studies of Ocular Complications of AIDS Research Group in Collaborat. Arch Ophthalmol. Jan 1996;114(1):23-33. [Medline].

  125. Studies of Ocular Complications of AIDS (SOCA) Research Group. Morbidity and toxic effects associated with ganciclovir or foscarnet therapy in a randomized cytomegalovirus retinitis trial. Studies of ocular complications of AIDS Research Group, in collaboration with the AIDS Clinical Trials Group. Arch Intern Med. Jan 9 1995;155(1):65-74. [Medline].

  126. Studies of Ocular Complications of AIDS (SOCA) Research Group. Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial. 4. Visual outcomes. Studies of Ocular Complications of AIDS Research Group in collaboration with the AIDS Clinical Trials Group. Ophthalmology. Jul 1994;101(7):1250-61. [Medline].

  127. Studies of Ocular Complications of AIDS (SOCA) Research Group. Studies of ocular complications of AIDS Foscarnet-Ganciclovir Cytomegalovirus Retinitis Trial: 1. Rationale, design, and methods. AIDS Clinical Trials Group (ACTG). Control Clin Trials. Feb 1992;13(1):22-39. [Medline].

  128. Tseng AL, Mortimer CB, Salit IE. Iritis associated with intravenous cidofovir. Ann Pharmacother. Feb 1999;33(2):167-71. [Medline].

  129. Tufail A, Moe AA, Miller MJ, et al. Quantitative cytomegalovirus DNA level in the blood and its relationship to cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. Ophthalmology. Jan 1999;106(1):133-41. [Medline].

  130. Tufail A, Weisz JM, Holland GN. Endogenous bacterial endophthalmitis as a complication of intravenous therapy for cytomegalovirus retinopathy. Arch Ophthalmol. Jul 1996;114(7):879-80. [Medline].

  131. Verbraak FD, van den Horn GJ, van der Meer JT, et al. Risk of developing CMV retinitis following non-ocular CMV end organ disease in AIDS patients. Br J Ophthalmol. Jul 1998;82(7):748-50. [Medline].

  132. Walmsley S, Tseng A. Comparative tolerability of therapies for cytomegalovirus retinitis. Drug Saf. Sep 1999;21(3):203-24. [Medline].

  133. Walsh JC, Jones CD, Barnes EA, et al. Increasing survival in AIDS patients with cytomegalovirus retinitis treated with combination antiretroviral therapy including HIV protease inhibitors. AIDS. Apr 16 1998;12(6):613-8. [Medline].

  134. Wattanamano P, Clayton JL, Kopicko JJ, et al. Comparison of three assays for cytomegalovirus detection in AIDS patients at risk for retinitis. J Clin Microbiol. Feb 2000;38(2):727-32. [Medline].

  135. Whitcup SM. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. JAMA. Feb 2 2000;283(5):653-7. [Medline].

  136. Whitcup SM, Fortin E, Lindblad AS, et al. Discontinuation of anticytomegalovirus therapy in patients with HIV infection and cytomegalovirus retinitis. JAMA. Nov 3 1999;282(17):1633-7. [Medline].

  137. Whitcup SM, Fortin E, Nussenblatt RB, et al. Therapeutic effect of combination antiretroviral therapy on cytomegalovirus retinitis. JAMA. May 21 1997;277(19):1519-20. [Medline].

  138. Whitcup SM. Cytomegalovirus Retinitis in the Era of Highly Active Antiretroviral Therapy. JAMA. 2000;283 No. 5:653-657.

  139. Whitcup, SM, Fortin, E, Linblad, AS. Discontinuation of Anticytomegalovirus Therapy in Patients With HIV Infection and Cytomegalovirus Retinits. JAMA. 1999;282:1633-1637.

  140. Whitley RJ, Jacobson MA, Friedberg DN, et al. Guidelines for the treatment of cytomegalovirus diseases in patients with AIDS in the era of potent antiretroviral therapy: recommendations of an international panel. International AIDS Society-USA. Arch Intern Med. May 11 1998;158(9):957-69. [Medline].

  141. Zegans M, Marsh B, Walton RC. Cytomegalovirus retinitis in the era of highly active antiretroviral therapy. Int Ophthalmol Clin. Spring 2000;40(2):127-35. [Medline].

  142. Zeichner SL. Foscarnet. Pediatr Rev. Dec 1998;19(12):399-400. [Medline].

[ CLOSE WINDOW ]

Further Reading

[ CLOSE WINDOW ]

Keywords

cytomegalovirus retinitis, CMV retinitis

[ CLOSE WINDOW ]

Contributor Information and Disclosures

Author

Michael Altaweel, MD, FRCS(C), Associate Professor, Department of Ophthalmology and Visual Sciences, University of Wisconsin School of Medicine and Public Health
Michael Altaweel, MD, FRCS(C) is a member of the following medical societies: American Academy of Ophthalmology and Association for Research in Vision and Ophthalmology
Disclosure: Nothing to disclose.

Coauthor(s)

Matthew D Reed, MD, Fellow, Department of Ophthalmology and Visual Sciences, University of Wisconsin Clinical Science Center
Disclosure: Nothing to disclose.

Medical Editor

Vytautas A Pakainis, MD, Chief of Ophthalmology, Dorn Veterans Administration Medical Center, Professor of Ophthalmology, Ophthalmology, University of South Carolina School of Medicine
Vytautas A Pakainis, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and South Carolina Medical Association
Disclosure: Nothing to disclose.

Pharmacy Editor

Simon K Law, MD, PharmD, Assistant Professor of Ophthalmology, Jules Stein Eye Institute; Chief of Section of Ophthalmology Surgical Services, Department of Veterans Affairs Healthcare Center, West Los Angeles
Simon K Law, MD, PharmD is a member of the following medical societies: American Academy of Ophthalmology, American Glaucoma Society, and Association for Research in Vision and Ophthalmology
Disclosure: Nothing to disclose.

Managing Editor

Steve Charles, MD, Director of Charles Retina Institute; Clinical Professor, Department of Ophthalmology, University of Tennessee College of Medicine
Steve Charles, MD is a member of the following medical societies: American Academy of Ophthalmology, American Society of Retina Specialists, Club Jules Gonin, Macula Society, and Retina Society
Disclosure: Alcon Laboratories Consulting fee Consulting

CME Editor

Lance L Brown, OD, MD, Ophthalmologist, Affiliated With Freeman Hospital and St John's Hospital, Regional Eye Center, Joplin, Missouri
Disclosure: Nothing to disclose.

Chief Editor

Hampton Roy Sr, MD, Associate Clinical Professor, Department of Ophthalmology, University of Arkansas for Medical Sciences
Hampton Roy Sr, MD is a member of the following medical societies: American Academy of Ophthalmology, American College of Surgeons, and Pan-American Association of Ophthalmology
Disclosure: Nothing to disclose.

 
 
HONcode

We subscribe to the
HONcode principles of the
Health On the Net Foundation

All material on this website is protected by copyright, Copyright© 1994- by Medscape.
This website also contains material copyrighted by 3rd parties.

DISCLAIMER: The content of this Website is not influenced by sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.